Prognostic value of pretreatment platelet count, fibrinogen and d-dimer levels in osteosarcoma patients: A meta-analysis

Xianfeng Li,Honghong Ren,Lipeng Peng,Jie Li
DOI: https://doi.org/10.1097/md.0000000000038463
IF: 1.6
2024-06-01
Medicine
Abstract:Current cancer statistics demonstrate that osteosarcoma accounts for approximately 30% of primary bone malignancies with a low annual incidence of 2 to 3 per million, nonetheless, osteosarcoma should not be ignored due to its highly aggressive, metastatic, and lethal characteristics, which resulted in the poor prognosis of many patients. [ 1 ] In recent years, novel therapeutic strategies including adjuvant chemotherapy, preoperative neoadjuvant chemotherapy, and other targeted therapies are burgeoning rapidly, [ 2 ] and their combination with surgical resection has made great advances and benefited patients tremendously with an increase of 5-year survival rate from 10% to 20% to 60% to 70%. [ 3 , 4 ] Notwithstanding, the prognosis of osteosarcoma is still poor because of its metastatic features, and a majority of patients may die of tumor metastasis, especially metastasis to lung, even without evidence of metastasis at the initial diagnosis. [ 1 , 5 ] Therefore, the need for some effective and predictive biomarkers for osteosarcoma patients is more and more emphasized, which may help clinicians identify the proper treatment, forecast the prognosis, and prolong the survival of patients.
medicine, general & internal
What problem does this paper attempt to address?